Joint Purification Systems (JPS) is a privately held company, which has completed enrollment in a phase 2 U.S. clinical study of a 7-day local antibiotic therapy for the treatment of periprosthetic joint infection (PJI). The X7 Spacer System with Vancomycin and Tobramycin for local irrigation is designated by the FDA as an Orphan Drug and a Fast Track, Qualified Infectious Disease Product. JPS intends to demonstrate significant clinical superiority, safety and time to complete treatment of the X7 Spacer System in its upcoming phase 3 clinical study.